Medexus Pharmaceuticals Inc.
MEDXF
$1.77
-$0.01-0.56%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 3.56M | 2.30M | 1.09M | -214.00K | 5.88M |
| Total Depreciation and Amortization | 6.19M | 5.88M | 5.77M | 5.81M | 5.84M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.03M | 8.24M | 8.82M | 10.78M | 5.24M |
| Change in Net Operating Assets | 3.58M | 5.78M | 7.01M | 2.34M | 4.01M |
| Cash from Operations | 23.37M | 22.20M | 22.69M | 18.71M | 20.97M |
| Capital Expenditure | -132.00K | -75.00K | -54.00K | -50.00K | -58.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1.59M | -2.96M | -3.09M | -3.21M | -3.42M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.76M | -2.72M | -216.00K | -216.00K | -161.00K |
| Cash from Investing | -4.48M | -5.75M | -3.36M | -3.48M | -3.64M |
| Total Debt Issued | 17.58M | 17.58M | 17.58M | 17.58M | 26.86M |
| Total Debt Repaid | -13.57M | -49.59M | -47.31M | -43.99M | -65.87M |
| Issuance of Common Stock | -- | 25.19M | 25.19M | 25.19M | 25.19M |
| Repurchase of Common Stock | -17.58M | -17.58M | -17.58M | -17.58M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4.76M | -4.62M | -4.45M | -4.25M | -4.67M |
| Cash from Financing | -18.33M | -29.03M | -26.58M | -23.05M | -18.49M |
| Foreign Exchange rate Adjustments | -331.00K | 51.00K | -87.00K | -2.00K | 95.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 228.00K | -12.53M | -7.33M | -7.81M | -1.06M |